[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 1990

Second Thoughts on 3,4-Methylenedioxymethamphetamine (MDMA) Neurotoxicity

Author Affiliations

University of California, Irvine Medical Center Department of Psychiatry and Human Behavior 101 City Dr S Rte 88 Orange, CA 92668

Arch Gen Psychiatry. 1990;47(3):288. doi:10.1001/archpsyc.1990.01810150088014
Abstract

To the Editor.—  Recent attention has been drawn to the purported neurotoxic dangers associated with 3, 4-methylenedioxymethamphetamine (MDMA). Price et al1 have attempted to assess possible serotonergic neurotransmitter damage by contrasting serum prolactin response to the challenge with intravenous L-tryptophan in subjects with a history of MDMA use vs control subjects. Their primary finding was a blunted rise in the expected serum prolactin level in MDMA users, but not to a statistically significant degree. The importance of this finding appears to be questionable and perhaps misleading. Even if the data had yielded a statistically significant result, would such a correlation necessarily imply causation?A methodological limitation to the study would appear to be that subjects were not adequately screened on selection to exclude those who were using other psychotropic drugs. There is no mention that toxicology screens were ever performed. In fact, three subjects (33%) admitted to marijuana use

First Page Preview View Large
First page PDF preview
First page PDF preview
×